NEW YORK (GenomeWeb News) – The genomics research services company BioServe will provide clinical biosample and other services to the Fairbanks Institute for Healthy Communities as part of its Indiana-based study of type 2 diabetes.
BioServe said today that it will support the Fairbanks Institute's contributions to the Indiana Health Study, which is a community-based initiative aimed at using the population of central Indiana in creating a research platform that will lead to the development of new diagnostics and drugs for diseases such as heart disease, cancer, and diabetes.
Beltsville, Md.-based BioServe said it already is processing samples for the coronary artery disease program, which began in 2008.
The Fairbanks type 2 diabetes study is enrolling 500 people with the disease, and 500 people matched by gender, ethnicity, and age but without type 2 diabetes or its risk factors, such as elevated BP and abnormal lipid profiles. The enrolled donors will provide blood and urine samples, as well as epigenetic, demographic, and clinical information at enrollment and again at the two-year and five-year points.
Clinical information for the study will be obtained for the Indiana Network for Patient Care, a health information exchange that connects five major health systems in Indianapolis, and includes more than 100 hospitals.
Financial terms of the agreement were not released.